Endo Health Solutions Offers Comment on Dismissal of Suit Against FDA

Endo Health Solutions Inc.(Nasdaq: ENDP) announced today that U.S. District Judge Reggie B. Walton, ofthe U.S. District Court for the District of Columbia, dismissed the case ofEndo's subsidiary, Endo Pharmaceuticals Inc., against the U.S. Food and DrugAdministration (FDA).  Endo Pharmaceuticals argued that FDA failed to meet itslegal obligation to determine in a timely manner whether the originalformulation of OPANA ER was withdrawn from the market for reasons of safety. The judge ruled against Endo, noting that he believes the FDA has not undulydelayed making a determination on the matter.  The FDA stated that it intendsto make its determination by May 2013. Endo reformulated OPANA ER to a version designed to be crush-resistant andlaunched this reformulated version in March 2012. The ruling by the court nowallows for a generic non-tamper resistant version to enter the market on Jan.2, 2013.